Current position on preparation and quality of leucodepleted platelet concentrates for clinical use

Double dose leucodepleted PC without filtration is considered to be the mos t cost-effective way of preparing leucodepleted PC in a reasonable time. Th e procedure lends itself to a multicomponent system and production of hyper concentrate and dry platelets, with <10-15 ml plasma in final product and v iral inactivation without considerable loss of in vitro platelet functions. Platelet concentrates obtained by various procedures are highly heterogeneo us, even if a standard protocol is used for the preparation. Therefore, sta ndard/standardisation in both production and testing procedures remain a ch allenging area in order to obtain comparative results. Attention needs to be focused on growing and complex technical features of preparation and on the use of new filter material in terms of biocompatibil ity and the related effects of activated factors on function of platelets a nd leucocytes. Both the production process and storage containers appear to contribute to various cellular lesion and generation of some biological re sponse modifiers such as complements, cytokines and microparticles. In this respect it is relevant to adopt a multiparameter analysis for the validati on of platelet quality as some markers of platelet storage lesion have diff erent affinity to various surfaces, leading to false under estimation. Further development work is still needed in preparation and usage of dry pl atelet, platelet alternative and bacterially safe products. The underlying conditions of the transfused patients is also an important i ssue in this respect, it is interesting to note that patients with high IL8 levels have a substantially lower platelet recovery. (C) 2000 Elsevier Sci ence Ltd. All rights reserved.